Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability,
 PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry
 a targeted single nucleotide polymorphism, rs362307 (SNP1). To participate in the study,
 patients must have completed the Phase 1b/2a clinical study WVE-HDSNP1-001.
Key Inclusion Criteria:

 -  1. Patient successfully completed the Phase 1b/2a study with WVE-120101,
 WVE-HDSNP1-001.

 Key Exclusion Criteria:

 -  1. Received an investigational drug other than WVE-120101, including an
 investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug,
 whichever is longer.

 -  2. Inability to undergo brain MRI (with or without sedation).

 -  3. Clinically significant medical finding on the physical examination other than HD
 that, in the judgment of the Investigator, will make the patient unsuitable for
 participation in and/or completion of the study procedures.